Huntingdon Life Sciences Group , Europe's biggest contract research organization using animal testing, has been the target of controversy since 1997, when a technician was caught on film mistreating a dog. Since then, the company has appointed new management and adheres closely to the UK's vigorous laws surrounding animal testing. But protests against it continue, and recently several UK financiers almost withdrew a loan from the company. HLS's problems represent a wider issue surrounding public support and understanding of scientific research in the UK. Much of Britain's public remains skeptical about scientific research, and the intentions of scientists and despite some efforts to form a cohesive statement supporting HLS, Britain's big pharma companies seem reluctant to publicly come to its aid, even some of those that use its services.
You may also be interested in...
Current in vivo and in vitro models can't keep up with the demand for the safety assessment of large numbers of compounds emerging from high-throughput strategies. Pharmaceutical companies and start-ups are therefore building new systems that they hope will be capable of predicting the toxicity liabilities of new compounds. Cheminformatics can help week out toxic compounds at the lead selection and optimization stage; toxicogenomics may provide a toxicity diagnostic capability at all stages of drug development. For both toxicology approaches, there is not yet enough high quality data to build predictive models. Toxicology-focused cheminformatics programs attempt to consolidate data from hitherto untapped sources; toxicogenomics companies are engaged in the fussy and expensive process of manufacturing data from scratch and validating them with biological experiments.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.